All In Biotech

Drug Trial Radar · NCT06669403

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

A Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Mar 9, 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Op-T LLCIndustry
Sponsor type
Industry
First posted
Nov 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis. This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.

Conditions

  • Sepsis
  • Community Acquired Pneumonia (CAP)

Interventions

  • OPT101Drug

    OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

  • PlaceboOther

    0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: 30 days
  2. Incidence of serious adverse events (SAEs)Time frame: 30 days
  3. Incidence of TEAEs leading to study drug discontinuationTime frame: 30 days
  4. Incidence and characteristics of presumed infusion reactionsTime frame: 30 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Denver Health and Hospital Authority

    Denver, Colorado · Not yet recruiting

  • Westchester Medical Center

    Valhalla, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.